Kymera Therapeutics, Inc. (KYMR)
Nasdaq: KYMR · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2020
Who owns Kymera Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Fmr LLC holds 14.3% of COMMON STOCK, as its SCHEDULE 13G/A filed May 6, 2026 says.
Directors and officers
30
report now, of 38 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · 11.2% in Jan 8, 2026
Baker Bros. Advisors LP
SCHEDULE 13D/A · filed Dec 11, 2025 · Common Stock, $0.0001 par value per share · 9.5% in Jun 30, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Sep 8, 2026 · COMMON STOCK · 8.6% in Aug 14, 2026
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G · filed May 15, 2026 · COMMON STOCK
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 5.4% in Jul 17, 2025
Bvf Partners L P/il
SCHEDULE 13D/A · filed Jun 26, 2026 · Common Stock, $0.0001 par value per share · 8.5% in Dec 15, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · reported falling below 5%, from 5.5% in Feb 10, 2026
Atlas Venture Fund X, L.P.
SCHEDULE 13G/A · filed Aug 13, 2026 · COMMON STOCK, $0.0001 PAR VALUE · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 8.05% in Apr 30, 2025
What KYMR reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
283sales
2purchases
241sales on a scheduled plan
11people selling
$479Msold, in dollars
$173Mbought, in dollars
Open-market trades on Form 4 from Oct 1, 2025 to Oct 1, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 1, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Booth Bruce | director | 160 | $226M | 146 | 0 | $0 |
| Biotechnology Value Fund II LP | director | 4 | $174M | 0 | 0 | $0 |
| Mainolfi Nello | Chief Executive Officer | 26 | $36.8M | 26 | 0 | $0 |
| Chadwick Jeremy G | Chief Operating Officer | 29 | $15.6M | 22 | 0 | $0 |
| Jacobs Bruce N. | Chief Financial Officer | 15 | $10.0M | 8 | 0 | $0 |
| Gollob Jared | Chief Medical Officer | 18 | $9.1M | 11 | 0 | $0 |
| Esposito Pamela | director | 12 | $3.1M | 12 | 0 | $0 |
| Goodman Noah | Chief Business Officer | 9 | $2.2M | 9 | 0 | $0 |
| Ridloff Elena | director | 4 | $1.3M | 4 | 0 | $0 |
| Adams Brian | Chief Legal Officer | 3 | $700,000 | 0 | 0 | $0 |
| Albers Jeffrey W. | director | 3 | $700,000 | 3 | 0 | $0 |
| Baker Felix | director | 0 | $0 | 0 | 2 | $173M |